TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00453895

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sunitinib
Description: 50mg Sunitinib
Study: NCT03520881

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pediatric ASTHMA-Educator mobile application
Description: This intervention represents a mobile application (accessible by iOS and Android devices) that provides asthma education through games and videos.
Study: NCT00822614

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fentanyl TAIFUN
Description: Inhalation of Fentanyl via TAIFUN inhaler

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Opioid
Description: Current optimized BTP treatment
Study: NCT04412759

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: microbial cellulose
Description: polymer dressing synthesized in abundance with Acetobacter Xylinum
Study: NCT03206762

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Jetstream Atherectomy with randomization to the Ranger or IN.PACT DCB Arm or the POBA+DCB (Ranger or IN.PACT) Arm
Description: Jetstream Atherectomy with randomization to the Ranger or IN.PACT DCB Arm or the POBA+DCB (Ranger or IN.PACT) Arm
Study: NCT03592901

Intervention type: DRUG
Intervention: brachial plexus anesthesia
Description: Anesthesia to some part of the brachial plexus prior to surgery. Patients are already receiving this regardless of participation in study.
Study: NCT02754986

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Analysis of the holter electrocardiogram
Study: NCT02032979

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Psychiatric test
Study: NCT02703090

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Remifentanil

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Remifentanil

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline
Study: NCT04390854

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Blood clot scaffold
Description: Bleeding will be induced in the canal by passing a size 30 sterile K-file 3 mm beyond the apex with the goal of having the entire canal filled with blood to the level of the cemento-enamel junction. Bleeding will be stopped just below the cemento enamel junction.~Biodentine will be placed approximately 3-4 mm below the cementoenamel junction.
Study: NCT02691533

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ω3 PUFA (Polyunsaturated fatty acids) (10% Omegavan 100 ml)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ω6 PUFA (Polyunsaturated fatty acids) (10% Intralipid 100 ml)
Study: NCT04390854

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Blood clot scaffold combined with PRF
Description: Platelet-rich fibrin will be prepared by drawing the patient blood into a 10mL test tube without the addition of an anticoagulant. To prevent the blood from coagulating after coming in contact with the glass tube, it will be centrifuged immediately using a table top centrifuge\*\* at 400 g force for 12 minutes. Then platelet-rich fibrin membrane will be placed into the canal space to a level 3 mm below the cemento-enamel junction using hand plugger following the induction of apical bleeding by passing a number 30 sterile hand file 3 mm beyond the apex of the tooth. Biodentine cap will be placed over the platelet-rich fibrin scaffold.
Study: NCT02584140

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Text Messaging
Description: All participants assigned to the iTAB intervention will receive daily dosing reminders that will be sent for the first 6 weeks and then continue with reminders for the duration of the study.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Adherence Counseling
Description: All participants assigned to the counseling intervention will receive sexual health and medication adherence counseling at each study visit. Participants with suboptimal adherence (TFV-DP levels of \<1050 fmol/punch (representing fewer than mean 6-7 daily doses per week)) will trigger a targeted iNSC session. Participants with two TFV-DP levels of \<1050 fmol/punch will trigger PrEP Steps, a higher intensity adherence counseling intervention consisting of four 50-minute counseling sessions and 2 booster counseling sessions.

Intervention type: DRUG
Group type: OTHER
Intervention: Daily Oral PrEP
Description: All participants will be offered daily oral emtricitabine/tenofovir disoproxil fumarate for Pre-exposure Prophylaxis.
Study: NCT02012309

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PCV-13

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PCV-13

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PPSV-23
Study: NCT01447264

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Land exercises
Description: 3 times a week. 50 minutes in every session. Performed by educational professor

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Water exercises
Description: 3 times a week. 50 minutes in every session. Performed by educational professor
Study: NCT00599209

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: clinical decision support
Description: CDS is provided to prescribers on intervention units upon ordering medication which offers advice on prescribing and monitoring practices
Study: NCT02470559

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Aldesleukin
Description: Given SC
Study: NCT03002961

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RBP-6000
Description: single dose of RBP-6000, preceded by a pharmacokinetic (PK) sample followed by serial PK samples post-dose. Additionally subjects to remain in the clinic through Day 21 for safety assessments

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RBP-6000
Description: single dose of RBP-6000, preceded by a pharmacokinetic (PK) sample followed by serial PK samples post-dose. Additionally subjects to remain in the clinic through Day 21 for safety assessments

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RBP-6000
Description: single dose of RBP-6000, preceded by a pharmacokinetic (PK) sample followed by serial PK samples post-dose. Additionally subjects to remain in the clinic through Day 21 for safety assessments

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RBP-6000
Description: single dose of RBP-6000, preceded by a pharmacokinetic (PK) sample followed by serial PK samples post-dose. Additionally subjects to remain in the clinic through Day 21 for safety assessments

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Suboxone
Description: RBP-6000 injection after 7 days of SL Suboxone administration. Interventions as above with additional daily PK collections during Suboxone treatment prior to RBP-6000 administration
Study: NCT02847962

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Corn Soy Blend Plus (CSB+)
Study: NCT02691533

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: No Lipid Emulsion/Placebo
Study: NCT04059653

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Electrical stimulation
Description: Electrical stimulation device

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Treatment as usual
Description: GP treatment as usual
Study: NCT03271554

Intervention type: DRUG
Intervention: Alectinib
Description: According to local labeling the recommended dose of alectinib is 600 mg given orally, twice daily with food (total daily dose of 1200 mg).
Study: NCT02878902

Intervention type: OTHER
Intervention: Post implementation
Description: Patient group whose care course was organized by the nurse coordinator of chronic renal failure
Study: NCT02847962

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Corn Soy Blend 14 (CSB14)
Study: NCT03587051

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Low glycemic index post-exercise diet
Description: Feeding of a low-glycemic index, lentil meal after 90 minutes of walking exercise

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: High glycemic index post-exercise diet
Description: Feeding of a high-glycemic index meal (i.e. instant mashed potatoes, white bread, egg whites) after 90 minutes of walking exercise
Study: NCT02842827

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bomedemstat
Description: oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bomedemstat
Description: oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bomedemstat
Description: oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bomedemstat
Description: oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bomedemstat
Description: oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bomedemstat
Description: oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bomedemstat
Description: oral administration
Study: NCT02847962

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: White Sorghum Cowpea Blend Variety 1

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: White Sorghum Cowpea Blend Variety 2

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Red Sorghum Cowpea Blend

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: White Sorghum Soy Blend
Study: NCT02961608

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Drug conversion from Tacrolimus (Prograf® or Adoport®) to LCP-Tacrolimus (Envarsus®)
Description: Drug conversion from Tacrolimus (Prograf® or Adoport®) to LCP-Tacrolimus (Envarsus®)
Study: NCT03770312

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Low intensity statin
Description: Use of low intensity statin for primary prevention of cardiovascular disease.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Moderate intensity statin
Description: Use of moderate intensity statin for primary prevention of cardiovascular disease.
Study: NCT03605667

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: troriluzole
Description: Oral BHV-4157 will be given daily for up to 48 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral capsule
Description: Oral matching placebo will be given daily for up to 48 weeks
Study: NCT04361435

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Chest physiotherapy using a non-invasive oscillating device
Description: NIOD will be implemented on four different parts of the chest walls, 3 minutes for each part and 12 minutes in total per each session. Left and right front and posterior chest walls will be stimulated, particularly, on the anterior chest, intercostal spaces 1-2 above nipple line and lateral side of the mid-clavicular line 1-2 below intercostal spaces. The intensity of the NIOD can be selected between 80-100%, which is pre-specified on the machine.

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Chest physiotherapy using a non-invasive oscillating device
Description: NIOD will be implemented on four different parts of the chest walls, 3 minutes for each part and 12 minutes in total per each session. Left and right front and posterior chest walls will be stimulated, particularly, on the anterior chest, intercostal spaces 1-2 above nipple line and lateral side of the mid-clavicular line 1-2 below intercostal spaces. The intensity of the NIOD can be selected between 80-100%, which is pre-specified on the machine.
Study: NCT02337413

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Polyethylene glycol 3350
Description: Patients will initially receive three days of high dose PEG3350 treatment (1.5gr/kg up to 100gr maximum) and then will be stepped down to 0.8gr/kg subsequently and tapered accoriding to stool consistency and frequency.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Constipation behavioral therapy
Description: Patients in the active group will receive dietary instruction as to fiber content, as well as behavioral therapy including active sitting on the toilet to attempt defaction following meals.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Urotherapy
Description: Patients will be guided for appropriate drinking and toilet habits, and will start with timed voiding.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Urotherapy
Description: Patients will be guided for appropriate drinking and toilet habits, and will start with timed voiding.
Study: NCT03380650

Intervention type: DEVICE
Group type: OTHER
Intervention: directional atherectomy and locol drug delivery
Description: combined use of directional atherectomy and locol drug delivery for the treatment of femoralpopliteal disease

Intervention type: DEVICE
Group type: OTHER
Intervention: drug-coated balloon dilation
Description: use of drug-coated balloon dilation for the treatment of femoralpopliteal disease
Study: NCT01769313

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Laser-assisted cataract surgery
Description: The anterior capsulotomy and lens fragmentation will be performed by means of femtosecond laser surgery

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Manually performed cataract surgery
Description: The anterior capsulotomy and lens fragmentation will be performed manually.
Study: NCT02981147

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Phytus (Cisti, Thyme and Ivy Leaves)
Description: Phytus is a medicinal herb containing Ivy leaves, Cisti and Thyme.
Study: NCT00149968

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enteric-Coated Mycophenolate Sodium (EC-MPS)
Description: Patient on MMF treatment completes questionnaire and switch to equimolar doses of Myfortic. Maximum daily dose 1440 mg
Study: NCT04827264

Intervention type: DIAGNOSTIC_TEST
Intervention: Safe Return to Play Following ACL Reconstruction Checklist
Description: All participants who have undergone primary ACL reconstruction will receive PT evaluation using our Return to Play Checklist at 7 months post-op, prior to return to sports
Study: NCT00584948

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Memantine
Description: Week 1: Take 5mg tab every morning. Week 2: Take 5mg tab every morning and evening. Week 3: Take 10mg tab in the morning and 5 mg in the evening. Week 4: Take 10 mg tab in the morning and evening, and remain on this dose through the remainder of the study.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Week 1: Take 5mg tab every morning. Week 2: Take 5mg tab every morning and evening. Week 3: Take 10mg tab in the morning and 5 mg in the evening. Week 4: Take 10 mg tab in the morning and evening, and remain on this dose through the remainder of the study.
Study: NCT04604535

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Concentrated beetroot juice
Description: 70mL concentrated beetroot juice (400mg nitrate)

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 70mL concentrated nitrate deplete beetroot juice (\<0.01mmol/L nitrate)
Study: NCT03444610

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Blood transfusion escalation rate
Description: 3+3 dose escalation (3 patients/cohort) each started on a fixed rate (standard is 5 ml/kg/ hr).1st cohort start at 6ml/kg/hr till complete prescribed volume. Rate escalation by 1ml/kg/each cohort until dose limiting toxicities (DLTs) or max of 10ml/kg/hr. If no DLTs new cohort enrolled at the next planned rate. If DLTs seen in 1 patient in the cohort, another 3 patients treated with the same dose level.1ry phase I end point is maximum-tolerated rate (MTR) of blood transfusion that can be infused safely ( max rate at which 1 or fewer of 3 patients experienced DLT) or dose of 10ml/kg/hr. DLT is transfusion related adverse event lead to stop of transfusion. MTR is highest dose at which no more than 1of 6 patients experienced a DLT.15 additional patients enrolled at MTR to confirm safety.
Study: NCT02931617

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Chest Physiotherapy

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Chest Physiotherapy

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Post-therapy lung volume measurements
Description: In both intervention groups.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Post-therapy lung volume measurements
Description: In both intervention groups.
Study: NCT00751686

Intervention type: PROCEDURE
Intervention: Stool sample
Description: Collection of the stool at least 48 hours after hospitalisation. Stool samples should be obtained preferably within 4 and no later than 10 days after the onset of the GE symptoms.

Intervention type: OTHER
Intervention: Data collection
Description: Logbook, Health Economic Questionnaire, Telephone call.
Study: NCT00879021

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Lyrica
Description: study participants will start will be on 150mg of Pregabalin or placebo capsules by mouth , twice a day.They will be on drug approx. 49 weeks and followed for another 49 weeks after stopping the medication.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: matching placebo
Description: 150 mg by mouth ,twice a day for 49 weeks
Study: NCT01574586

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Bifurcation stenting
Description: Bifurcation stenting using 2-link stent Nobori versus 3-link stent Xience

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Bifurcation stenting
Description: Bifurcation stenting using 2-link stent Nobori versus 3-link stent Xience
Study: NCT02728180

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Xingnaojing injection
Description: Xingnaojing injection (20 ml), IV (in the vein), every 12 hours for 10 days.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard care
Description: Guidelines-based standard care for acute ischemic stroke.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard care
Description: Guidelines-based standard care for acute ischemic stroke.
Study: NCT03755921

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: bried and intensive therapy
Description: Speech Therapy Exercises

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: bried and intensive therapy
Description: Speech Therapy Exercises
Study: NCT04546035

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: radial Extracorporeal Shockwave Therapy
Description: rESWT was given on hamstring muscles, with the subject lying on prone position. No anesthesia was required.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: radial Extracorporeal Shockwave Therapy
Description: rESWT was given on hamstring muscles, with the subject lying on prone position. No anesthesia was required.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: radial Extracorporeal Shockwave Therapy
Description: rESWT was given on hamstring muscles, with the subject lying on prone position. No anesthesia was required.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: radial Extracorporeal Shockwave Therapy
Description: rESWT was given on hamstring muscles, with the subject lying on prone position. No anesthesia was required.
Study: NCT00657540

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Analatro
Description: 30 mL of lyophilized antivenom, reconstituted in 50 mL saline infused over 10 minutes, up to 2 doses

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: 50 mL of saline infused over 10 minutes
Study: NCT03552666

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: vitamin D3

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: vitamin D3
Study: NCT06125366

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAY1747846
Description: Single dose; IV injection.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Matching placebo
Description: Single dose; IV injection.
Study: NCT01848665

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Indomethacin

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT01796925

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: aura6000 THN System
Description: The aura6000 device is an implanted hypoglossal nerve stimulator designed to maintain wakeful muscle tone of the tongue during sleep. It is implanted through a short surgical procedure. The implant is programmed to provide the optimal stimulation parameters for the patient. The therapy is controlled by a hand-held remote control allowing the patient to start, stop, and pause the therapy during times of sleep.
Study: NCT00602212

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: relaxation with virtual reality (VR)
Description: VR relaxing environment and audio-visual mobile narratives will be used to teach patients how to relax themselves

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: relaxation with virtual reality (VR)
Description: VR relaxing environment and audio-visual mobile narratives will be used to teach patients how to relax themselves

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: relaxation and biofeedback virtual reality
Description: The patients experienced the same protocol described above, but with the biofeedback support. Specifically, in the sessions with the therapist, HR variations were used to modify specific features of the virtual environment:

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: relaxation and biofeedback virtual reality
Description: The patients experienced the same protocol described above, but with the biofeedback support. Specifically, in the sessions with the therapist, HR variations were used to modify specific features of the virtual environment:
Study: NCT04393675

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: LT5001
Description: Administered twice daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered twice daily
Study: NCT02836912

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise
Description: Besides the same information for the education group, exercise of upper extremity without loading, exercise of lower extremity, and training of respiratory muscles are used for the exercise group
Study: NCT02828371

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: stepping verticalization
Description: After patient positioning, the slope of the tilt table was gradually increased from 0° to 20°, 40° and then 60° in a time span of nine minutes. The stepping frequency was set at 20 steps/min for the entire treatment. Cardiovascular and respiratory parameters were continuously monitored. The net time of the session was 30 minutes

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: conventional mobilization
Description: in-bed physiotherapy (mobilization exercises in supine and sitting position on bed, without out-of-bed mobilization nor verticalization)
Study: NCT03128515

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hydroxyurea
Description: Administered once a day in tablet form (100mg or scored 1000mg) for 24 months

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydroxyurea
Description: Administered once a day in tablet form (100mg or scored 1000mg) for 24 months